{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:29Z","timestamp":1791332309622,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jpsychires.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T13:56:06Z","timestamp":1547474166000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis"],"prefix":"10.1016","volume":"111","author":[{"given":"Dong-Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Mao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2019.01.014_bib1","article-title":"A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy","author":"Albert","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib3","first-page":"231","article-title":"Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder","volume":"1","author":"Aouizerate","year":"2005","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib4","article-title":"The efficacy of aripiprazole versus risperidone as augmentation therapy in treatment-resistant obsessive-compulsive disorder: A double blind clinical trial","volume":"20","author":"Assarian","year":"2018","journal-title":"Iran. Red Crescent Med. J."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","article-title":"Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study","volume":"17","author":"Atmaca","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib8","first-page":"321","article-title":"Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?","volume":"27","author":"Carey","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-244X-5-5","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study","volume":"5","author":"Carey","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopsych.2006.12.014","article-title":"Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?","volume":"61","author":"Denys","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biopsych.2004.01.023","article-title":"Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder","volume":"55","author":"Denys","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib13","series-title":"NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011","author":"Dias","year":"2011"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib15","doi-asserted-by":"crossref","first-page":"763\u2010768","DOI":"10.1097\/JCP.0b013e3182367aee","article-title":"A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder","volume":"31","author":"Diniz","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib18","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","article-title":"D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis","volume":"231","author":"Ducasse","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","article-title":"Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study","volume":"20","author":"Fineberg","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.yic.0000215083.57801.11","article-title":"Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials","volume":"21","author":"Fineberg","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib23","doi-asserted-by":"crossref","first-page":"397\u2010401","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib24","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2019.01.014_bib25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000106474","article-title":"Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors","volume":"55","author":"Kim","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib27","article-title":"Second-generation antipsychotics for obsessive compulsive disorder","volume":"CD008141","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","article-title":"8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder","volume":"18","author":"Maina","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib30","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hup.512","article-title":"Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial","volume":"18","author":"Metin","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study","volume":"31","author":"Muscatello","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2000-8360","article-title":"Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs","volume":"33","author":"Ramasubbu","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0079-6123(08)00908-4","article-title":"Role of serotonin and dopamine receptor binding in antipsychotic efficacy","volume":"172","author":"Richtand","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hup.1169","article-title":"The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study","volume":"26","author":"Selvi","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib40","doi-asserted-by":"crossref","first-page":"553\u2010555","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib41","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4088\/JCP.v66n1204","article-title":"Clinical predictors of drug nonresponse in obsessive-compulsive disorder","volume":"66","author":"Shetti","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2045125314560739","article-title":"Aripiprazole versus quetiapine in treatment-resistant obsessive\u2013compulsive disorder: a double-blind clinical trial","volume":"5","author":"Shoja Shafti","year":"2015","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","article-title":"Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials","volume":"17","author":"Skapinakis","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib46","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.4088\/JCP.12m08278","article-title":"Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder","volume":"74","author":"Storch","year":"2013","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.014_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.014_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0020764009347333","article-title":"Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorder","volume":"57","author":"Vikas","year":"2011","journal-title":"Int. J. Soc. Psychiatr."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618312342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618312342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T14:45:28Z","timestamp":1557240328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618312342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":48,"alternative-id":["S0022395618312342"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.014","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}